Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MONTHLY LHRH AGONIST TO 6-MONTHLY INJECTIONS OF DECAPEPTYL SR 22.5 MG

Next Previous
X
Search
Trial Profile

A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MONTHLY LHRH AGONIST TO 6-MONTHLY INJECTIONS OF DECAPEPTYL SR 22.5 MG

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary) ; Goserelin; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms GREAT
  • Sponsors Ipsen

    • Most Recent Events

    • 28 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 29 Apr 2014 According to the ClinicalTrials.gov reciord, status changed from active, no longer recruiting to completed.
    • 06 Feb 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Sep 2014 to 1 Feb 2014.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top